Safety and Efficacy of VDMN-21 Patch in Subjects With Common Warts
Trial details
- Registry ID
- NCT05799157
- Phase
- Phase 2
Company identity checked against sources
Browse linked trials and recorded changes, or follow this company for updates.
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Safety and Efficacy of VDMN-21 Patch in Subjects With Common WartsNCT05799157 | MANE | Phase 2 | Completed | 2025-02-25Actual |
| Safety and Efficacy of VDPHL01 in Males and Females With AGANCT06527365 | MANE | Phase 2 | Active not recruiting | 2026-08Estimated |
| Efficacy and Safety of VDPHL01 in Males With AGANCT06724614 | MANE | Phase 2, Phase 3 | Active not recruiting | 2026-02Estimated |
| Safety and Efficacy of VDPHL01 in Males With AGANCT06972264 | MANE | Phase 3 | Active not recruiting | 2026-12Estimated |
| Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA)NCT07146022 | MANE | Phase 3 | Active not recruiting | 2027-06Estimated |
NCT07146022 · Veradermics, Inc.
Recruiting
Active not recruiting
NCT06972264 · Veradermics, Inc.
Recruiting
Active not recruiting
NCT07146022 · Veradermics, Inc.
Mar 2027
Jun 2027
NCT06527365 · Veradermics, Inc.
28 Feb 2026
Aug 2026
NCT06724614 · Veradermics, Inc.
Jul 2026
Feb 2026
NCT06972264 · Veradermics, Inc.
Nov 2026
Dec 2026